Nova Eye Medical (ASX:EYE) Surges Ahead with Record FY25 Revenues

2 min read | July 08, 2025 06:25 PM AEST | By Team Kalkine Media

Nova Eye Medical (ASX:EYE) Surges Ahead with Record FY25 Revenues — Image source: Shutterstock

Sales Momentum Strengthens in H2FY25

The second half of FY25 proved to be a pivotal growth period for Nova Eye Medical. The company’s H2 sales reached A$15.7 million, building on an already strong first half. This continued expansion reflects both strategic market penetration and growing recognition of the company’s minimally invasive glaucoma surgery (MIGS) solutions.

A particularly notable contributor to this growth was the performance in the US market, which remains a cornerstone of the company’s commercial strategy. The company’s flagship device, iTrack™ Advance, has sustained momentum in the US for six consecutive half-year periods, illustrating consistent market acceptance and clinician engagement.

Record Performance in US Market

US-based sales reached a new peak, totaling US$14.2 million, aided by recurring clinical demand and strategic sales efforts. The fourth quarter of FY25 alone delivered a record A$8.4 million in sales, reinforcing Nova Eye Medical’s trajectory of accelerating revenue in its largest market.

The commercial expansion in North America underscores the company’s strength in the global ophthalmic device industry. With a focused portfolio and established market channels, the business continues to develop its presence in key international markets while investing in clinician support and product innovation.

Positioned for Continued Growth

Nova Eye Medical’s record results position the company to further its ambitions in the fast-growing ophthalmology segment. The continued uptake of its MIGS platform aligns with healthcare trends prioritizing effective, non-invasive solutions for chronic eye conditions such as glaucoma.

While the company does not currently feature in the ASX 100 companies, its momentum could place it on the radar of institutional investors seeking exposure to innovative med-tech players in the small- to mid-cap space.

Nova Eye Medical’s latest fiscal performance offers a strong signal of its operational execution and market positioning. As healthcare markets continue to evolve, the company appears well-aligned with sectoral trends focused on minimally invasive and patient-centric technologies.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.